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The Rate of Progression and Ocular
Perfusion Pressure in the Low-
Pressure Glaucoma Treatment Study
EDITOR:
THE LOW-PRESSURE GLAUCOMA TREATMENT STUDY IS THE
first multicenter, randomized, double-masked, controlled
clinical trial comparing the efficacy of topical twice-daily
brimonidine tartrate 0.2% and twice-daily timolol maleate
0.5% in reducing intraocular pressure (IOP) to prevent or
delay visual field progression in patients with low-pressure
glaucoma, more commonly called normal-tension glau-
coma (NTG).1
In our opinion, some considerations have to be taken
into account before claiming its findings will change our
clinical practice. Eligibility of patients based on IOP was
assessed throughout a diurnal curve, with no IOP measure-
ment taken at nighttime or at least in supine position.
Exclusion of false diagnosis of NTG with IOP values of
more than 21 mm Hg during either daytime or nighttime
is mandatory in clinical and therapeutic studies, because it
accounts for between 11% and 20% of the suspected cases
of NTG.2
NTG is a group of progressive optic neuropathies shar-
ing a slow progressive degeneration of retinal ganglion cells
and their axons, resulting in typical optic disc damage,
visual field defects compatible with the glaucomatous
cupping, and progression of the disease. The requirement
that the disease be progressive is controversial. NTG
usually is a progressive disease, although this may not be
manifest for several years. Nevertheless, the progressive
nature of the disease always should be borne in mind,
because this will help to distinguish true NTG from an
isolated ischemic event that may mimic it in terms of optic
disc and visual field appearances.3 The authors made no
mention of the rate of progression of the patients before
randomization, nor if this variable was evaluated at the
baseline, to take it into account in the design (ie, stratified
randomization) or in the statistical analysis.
Moreover, we previously showed that both timolol and
brimonidine are able to reduce blood pressure throughout
a 24-hour period in primary open-angle glaucoma
(POAG) patients4; thus, in patients affected by NTG,
AMERICAN JOURNAL OF880ecause of an abnormal vascular autoregulatory system,
he use of these 2 drugs should be avoided so as not to
nduce further reduction of ocular perfusion pressure
nd greater fluctuations.5
Beyond the clinical considerations, the survival analysis
is flawed by not taking into account the effect of compet-
itive risk on the correct estimation of the relative efficacy
of the treatments. In fact, the authors mentioned that 36
patients (37%) assigned to brimonidine and 8 patients
(10%) to timolol dropped out within 1 year from random-
ization mainly for reasons related to study treatments, such
as allergy or low compliance. The lack of following up
these patients until the end of the study compromises the
correct interpretation of the efficacy results. Supportive
analyses by using a composite end point, such as time to
treatment failure for any cause, and a competitive risk
analysis6 would have been of help to facilitate the text
comprehension and to increase the strength of the results.
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OPHTHALMOLOGY NOVEMBER 2011
